Elizabeth McFarland, MD

Professor, Pediatrics-Infectious Diseases


FacultyPhoto
Medical School
  • MD, Duke University School of Medicine (1985)
Undergraduate School
  • BS, Northwestern University (IL) (1981)
Internship
  • University of Colorado (University Hospital) Program (1986)
Residency
  • University of Colorado (University Hospital) Program, Pediatrics (1988)
Fellowships
  • University of Colorado (University Hospital) Program, Pediatric Infectious Diseases (1992)
Languages
English
Department
Pediatrics-Infectious Diseases

Professional Titles

  • Section Chief, Pediatric Infectious Diseases
  • Medical Director, Children's Hospital Colorado HIV Program
  • Professor of Pediatrics

Research Interests

Dr. McFarland’s primary areas of research interest are HIV passive and active immunization and immune-based HIV therapy, the role of HIV-specific cell-mediated immunity in HIV pathogenesis and response to therapy and RSV vaccine clinical trials. She is leading clinical research protocols focused on HIV-1 specific broadly neutralizing monoclonal antibody (bNAb) for infants exposed to HIV-1 and for infant early antiretroviral treatment. She serves as Vice Chair of the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) HIV Cure Committee, as member of the Pediatric Advisory Committee to the HIV Vaccine Trials Network (HVTN), as a co-investigator for the Pediatrics Adolescent Virus Eradication (PAVE) Martin Delaney Collaboratory, site principal investigator for the multicenter Pediatric AIDS/HIV Cohort Study (PHACS), and member of the PHACS Nutrition, Metabolic, Growth Working Group. She has served on the AIDS Research Advisory Council, Division of AIDS (DIADS) at the National Institutes of Health (NIH). Dr. McFarland has had continuous NIH and HRSA funding since 1995.

Publications

  • Cunningham CK, McFarland EJ, Muresan P, Capparelli EV, Perlowski C, Johnston B, Bone F, Purdue L, Yin DE, Moye J, Spiegel HML, Majji S, Theron GB, Mujuru HA, Purswani M, Alvarez G, Deville JG, Chambers C, Brown E, Harding PA, Tobin NH, Low K, Gama L. Safety, Tolerability, and Pharmacokinetics of Long-Acting Broadly Neutralizing HIV-1 Monoclonal Antibody VRC07-523LS in Newborn Infants Exposed to HIV-1. J Pediatric Infect Dis Soc. 2025 Feb 6;14(2). PubMed PMID: 39821046
  • Kelly MS, Cunningham CK, McFarland EJ, Giganti MJ, Lindsey JC, Perlowski C, Libous JL, Jean-Philippe P, Moye J Jr, Karron RA, Collins PL, Buchholz UJ. Infectivity and Immunogenicity of Live-Attenuated Respiratory Syncytial Virus Vaccines in Human Immunodeficiency Virus-Exposed Uninfected Children. Open Forum Infect Dis. 2024 Dec;11(12):ofae679. PubMed PMID: 39610407
  • DiMeglio LA, Yu W, Kalkwarf HJ, Brummel S, Chen JS, Geffner ME, McFarland EJ, Mirza A, Patel K, Shiau S, Jacobson DL. Bone Accrual Trajectories in Children and Adolescents with Perinatal HIV Infection. J Clin Endocrinol Metab. 2024 Sep 23. [Epub ahead of print] PubMed PMID: 39312415
  • Dugdale CM, Ufio O, Alba C, Permar SR, Stranix-Chibanda L, Cunningham CK, Fouda GG, Myer L, Weinstein MC, Leroy V, McFarland EJ, Freedberg KA, Ciaranello AL. Cost-effectiveness of broadly neutralizing antibody prophylaxis for HIV-exposed infants in sub-Saharan African settings. J Int AIDS Soc. 2023 Jan;26(1):e26052. PubMed PMID: 36604316
  • Melvin AJ, Yee KL, Gray KP, Yedla M, Wan H, Tobin NH, Teppler H, Campbell H, McCarthy K, Scheckter R, Aurpibul L, Ounchanum P, Rungmaitree S, Cassim H, McFarland E, Flynn P, Cooper E, Krotje C, Townley E, Moye J, Best BM. Pharmacokinetics, Tolerability, and Safety of Doravirine and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living With HIV: Week 24 Results From IMPAACT 2014. J Acquir Immune Defic Syndr. 2023 Feb 1;92(2):153-161. PubMed PMID: 36215957

Professional Memberships

  • Pediatric Infectious Disease Society, Member

Practice Locations

Children's Hospital Colorado Anschutz Medical Campus
13123 East 16th Ave
Aurora, CO 80045
720-777-1234

Hospital Affiliation
  • Children's Hospital Colorado

Specialty Information

Specialties
  • Pediatric Infectious Diseases, Board Certification (1992, 2008)
  • Pediatrics, Board Certification (1990, 2014)
Conditions & Treatments
  • Immune System - AIDS / HIV Disease
  • Immune System - AIDS Immunization
  • Infections - Bacterial Infections
  • Infections - Fungal Infections
  • Infections - Influenza
  • Infections - Pneumonia
  • Infections - Viral Infections
  • Infections
  • Immune System - AIDS
  • Symptoms and Manifestations - Fever
  • Immune System
  • Symptoms and Manifestations
  • Kawasaki Disease
Clinical Interests
I am interested in pediatric infectious diseases, particularly pediatric and perinatal HIV Infection.